| abstract |
The invention discloses the application of a novel ginsenoside in the preparation of an anti-myocardial fibrosis drug, and belongs to the technical field of medicine. The medicament comprises an effective amount of 20(R)-25 hydroxy-dammarane-3β, 12β, 20 triol and a pharmaceutically acceptable carrier, which can downregulate CollagenI, CollagenIII, PDGFR, HO in myocardial fibrosis subjects The mRNA expression levels of ‑1 and TIMP‑1 can reduce the generation of ROS in subjects with myocardial fibrosis and down-regulate the expression of PAI‑1 and α‑SMA proteins in subjects with myocardial fibrosis. This will provide a new drug treatment strategy for the clinical treatment of myocardial fibrosis, and also lay a theoretical and experimental foundation for the development of innovative drugs with independent intellectual property rights. |